Evidence map›Paper›PMID 39650643›Full record

ReviewFrontiers in immunology2024

Advances in protein subunit vaccines against H1N1/09 influenza.

Yu Zhang, Jingyao Gao, Wenqi Xu, Xingyu Huo, Jingyan Wang, Yirui Xu, Wenting Ding, Zeliang Guo, Rongzeng Liu

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. A Modular Vaccine Platform Against SARS-CoV-2 Based on Self-Assembled Protein Nanoparticles.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yu Zhang *Department of Immunology, College of Basic Medicine and Forensic Medicine, Henan University of Science and Technology, Luoyang, China.
Jingyao Gao *Department of Immunology, College of Basic Medicine and Forensic Medicine, Henan University of Science and Technology, Luoyang, China.
Wenqi XuDepartment of Immunology, College of Basic Medicine and Forensic Medicine, Henan University of Science and Technology, Luoyang, China.
Xingyu HuoDepartment of Immunology, College of Basic Medicine and Forensic Medicine, Henan University of Science and Technology, Luoyang, China.
Jingyan WangDepartment of Immunology, College of Basic Medicine and Forensic Medicine, Henan University of Science and Technology, Luoyang, China.
Yirui XuDepartment of Immunology, College of Basic Medicine and Forensic Medicine, Henan University of Science and Technology, Luoyang, China.
Wenting DingDepartment of Immunology, College of Basic Medicine and Forensic Medicine, Henan University of Science and Technology, Luoyang, China.
Zeliang GuoDepartment of Immunology, College of Basic Medicine and Forensic Medicine, Henan University of Science and Technology, Luoyang, China.
Rongzeng LiuDepartment of Immunology, College of Basic Medicine and Forensic Medicine, Henan University of Science and Technology, Luoyang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The A/H1N1pdm09 influenza virus, which caused the 2009 pandemic, has since become a recurring strain in seasonal influenza outbreaks. Given the ongoing threat of influenza, protein subunit vaccines have garnered significant attention for their safety and effectiveness. This review seeks to highlight the latest developments in protein subunit vaccines that specifically target the A/H1N1pdm09 virus. It will also examine the structure and replication cycle of influenza A viruses and compare different types of influenza vaccines. Additionally, the review will address key aspects of H1N1 protein subunit vaccine development, such as antigen selection, protein expression systems, and the use of adjuvants. The role of animal models in evaluating these vaccines will also be discussed. Despite challenges like antigenic variability and the complexities of vaccine production and distribution, protein subunit vaccines remain a promising option for future influenza prevention efforts.

Indexed as

Influenza A Virus, H1N1 SubtypeInfluenza, HumanInfluenza VaccinesVaccines, SubunitAdjuvants, ImmunologicAnimalsHumansProtein Subunit VaccinesVaccine DevelopmentAdjuvants, ImmunologicInfluenza VaccinesProtein Subunit VaccinesVaccines, SubunitadjuvantA/H1N1pdm09animal modelinfluenza vaccineyeast

Identifiers

PMID39650643
PMCPMC11621219

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.